Acelyrin’s Thyroid Eye Disease Drug Shows Promise in Phase II, But Investors Remain Skeptical
Acelyrin’s lonigutamab showed promise in Phase II trials for thyroid eye disease, reducing proptosis and improving vision. However, revised dosing for Phase III and a delayed timeline contribute to investor skepticism.